‘Mismatch repair’ genetic defects drive cancer patient’s response to immunotherapy drugs – News-Medical.net
|
'Mismatch repair' genetic defects drive cancer patient's response to immunotherapy drugs
News-Medical.net In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer … |
